Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SENATE PRODUCT LIABILITY BILL CAST AS SPUR TO ECONOMY

Executive Summary

SENATE PRODUCT LIABILITY BILL CAST AS SPUR TO ECONOMY by its five Senate sponsors who introduced the legislation March 31. The bipartisan measure was jointly introduced by principal author Sen. Rockefeller (D-W.Va.) and four cosponsors: Dodd (D-Conn.), Lieberman (D-Conn.), Gorton (R-Wash.) and Danforth (R-Mo.). Rockefeller said the bill will "break the gridlock in our civil courts" and "bring new efficiencies to our economy." Lieberman asserted that the bill is both "pro-business and pro- consumer at the same time." Gorton maintained that product liability reform will both improve U.S. companies' international competitiveness and encourage development of products that previously were not developed due to liability concerns. Like past iterations of product liability reform legislation, this year's bill includes a government standards defense that exempts products subject to FDA review from liability for punitive damages, as long as their marketers have not withheld or misrepresented material information about the products. One difference between the current bill and S 640, introduced in the 102nd Congress by ex-Sen. Kasten (R-Wisc.), is that claimants no longer would be penalized for refusing to participate in an alternative dispute resolution in a case subsequently lost. On the other hand, defendant companies under the current bill must pay reasonable legal fees and costs for the claimant if they refuse to pursue expedited settlement and subsequently lose. Rockefeller explained that after one of last year's votes on S 640, "a number" of Democratic senators expressed concern about the provision penalizing injured parties who lose their cases. The new bill "entirely satisfies that particular sentiment," he said. Danforth and Rockefeller added that S 640 for "about 45 minutes" had a super majority of 60 votes required to pass the bill and end debate, but the bill failed after a few senators changed their votes. They feel the changed provision could give the new bill the boost needed for Senate endorsement. Information about the legislation has been presented to the White House, Rockefeller said. Although President Clinton has not given any commitment to support the legislation, Rockefeller said that, in the past, the President has given indications that he might endorse such a bill. President Clinton, when he was governor of Arkansas, "twice has voted with other governors to establish uniform national federal product liability laws," the West Virginia Democrat said. In addition, the President in February told business leaders "that he recognizes that there has to be some kind of change in the tort system, [although] he didn't specify" what changes he thought were necessary. Furthermore, Clinton "has talked from time to time about the alternative dispute resolution system, which is a state system, after all," Rockefeller said. "But having said that, there is no commitment from the White House at all."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS022404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel